Cost-effectiveness analysis of oxaliplatin/5-fu/lv in adjuvant treatment of stage III colon cancer in the UK and Germany

被引：0
|
作者：
Aballea, S
Chancellor, J
Raikou, M
Drummond, M
Diel, R
Frick, M
Rosenfeld, S
Boler, A
Jourdan, S
Paulo, C
Bridgewater, J
机构：
[1] Innovus Res UK Ltd, High Wycombe, Bucks, England
[2] London Sch Econ, London, England
[3] Univ Dusseldorf, D-4000 Dusseldorf, Germany
[4] Aventis Pharma Deutschland GmbH, Berlin, Germany
[5] Heron Evidence Dev, Letchworth Garden City, England
[6] Sanofi Aventis R&D, Bagneux, France
[7] UCL Royal Free & Univ Coll Med Sch, London, England
来源：
VALUE IN HEALTH | 2005年 / 8卷 / 06期
关键词：
D O I：
10.1016/S1098-3015(10)67203-8
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A21 / A21
页数：1
相关论文
共 50 条
  • [1] Cost-effectiveness analysis of oxaliplatin/5-FU/LV in adjuvant treatment of stage III colon cancer in the UK
    Aballea, S.
    Chancellor, J. V. M.
    Raikou, M.
    Drummond, M. F.
    Jourdan, S.
    Carita, P.
    Bridgewater, J.
    Boler, A.
    EJC SUPPLEMENTS, 2005, 3 (02): : 178 - 178
  • [2] Cost-effectiveness analysis of oxaliplatin/5-FU/LV in adjuvant treatment of stage III colon cancer in Germany
    Aballea, S.
    Frick, M.
    Diel, R.
    Rosenfeld, S.
    Huppertz, E.
    Sievert, M.
    Jourdan, S.
    Drummond, M.
    Weinstein, M. C.
    Reichardt, P.
    EJC SUPPLEMENTS, 2005, 3 (02): : 182 - 183
  • [3] Cost-effectiveness analysis of oxaliplatin/5-FU/LV in adjuvant treatment of stage III colon cancer in the US
    Aballea, S
    Chancellor, J
    Raikou, M
    Drummond, M
    Weinstein, M
    Jourdan, S
    Carita, P
    Bridgewater, J
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 254S - 254S
  • [4] Cost-effectiveness of oxaliplatin and capecitabine in the adjuvant treatment of stage III colon cancer
    S Eggington
    P Tappenden
    A Pandor
    S Paisley
    M Saunders
    M Seymour
    P Sutcliffe
    J Chilcott
    British Journal of Cancer, 2006, 95 : 1195 - 1201
  • [5] Cost-effectiveness of oxaliplatin and capecitabine in the adjuvant treatment of stage III colon cancer
    Eggington, S.
    Tappenden, P.
    Pandor, A.
    Paisley, S.
    Saunders, M.
    Seymour, M.
    Sutcliffe, P.
    Chilcott, J.
    BRITISH JOURNAL OF CANCER, 2006, 95 (09) : 1195 - 1201
  • [6] Cost-effectiveness analysis of oxaliplatin compared with 5-fluorouracil/leucovorin in adjuvant treatment of stage III colon cancer in the US
    Aballea, Samuel
    Chancellor, Jeremy V. M.
    Raikou, Maria
    Drummond, Michael F.
    Weinstein, Milton C.
    Jourdan, Sophia
    Bridgewater, John
    CANCER, 2007, 109 (06) : 1082 - 1089
  • [7] Cost-Effectiveness of Adjuvant FOLFOX and 5FU/LV Chemotherapy for Patients with Stage II Colon Cancer
    Ayvaci, Mehmet U. S.
    Shi, Jinghua
    Alagoz, Oguzhan
    Lubner, Sam J.
    MEDICAL DECISION MAKING, 2013, 33 (04) : 521 - 532
  • [8] Cost-effectiveness of oxaliplatin in the adjuvant treatment of colon cancer in Canada
    Attard, C. L.
    Maroun, J. A.
    Alloul, K.
    Grima, D. T.
    Bernard, L. M.
    CURRENT ONCOLOGY, 2010, 17 (01) : 11 - 18
  • [9] COST-MINIMIZATION ANALYSIS OF XELOX (CAPECITABINE plus OXALIPLATIN) VERSUS FOLFOX-4 (5-FU/LV + OXALIPLATIN) AS ADJUVANT TREATMENT IN STAGE III COLON CANCER UNDER THE BRAZILIAN PRIVATE PAYER PERSPECTIVE
    Prolla, G.
    Borges, L. G.
    Santos, E.
    VALUE IN HEALTH, 2010, 13 (07) : A268 - A269
  • [10] Capecitabine (X) vs. mayo clinic and de Gramont 5-FU/LV regimens for stage III colon cancer: Cost-effectiveness analysis in the French setting
    Husseini, F.
    Douillard, J.
    Ychou, M.
    Perrocheau, G.
    Tilleul, P.
    Maes, P.
    Dufour, P.
    Seitz, J.
    ANNALS OF ONCOLOGY, 2006, 17 : 64 - 64
12345